Pharmaceutical

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.

Aug 21, 2024 - 04:00
J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC
J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.
Read the original article

Tags:

Previous Article

Adcendo and Multitude ink ADC deal potentially worth $1bn

Next Article

ReAlta secures FDA orphan drug and fast track designations for GvHD therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Plus Therapeutics and PPS expand partnership for cGMP drug production

Plus Therapeutics and PPS expand partnership for cGMP d...

May 2, 2023

US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410

US FDA grants orphan drug status to IN8bio’s INB-400 an...

Apr 26, 2023

STAT+: Pharmalittle: Pharma execs call for reversal of abortion pill ruling; U.S. to spend $5 billion to speed Covid-19 treatments

STAT+: Pharmalittle: Pharma execs call for reversal of ...

Apr 11, 2023